

Registration, Fees and Bursaries

The previous meeting was very popular and oversubscribed such that capacity has been increased to 140 attendees for 2019. Discounted rates are offered to RSC members. Registration fees include the Tuesday evening welcome buffet.

Early rates for payments received by 22nd March

£525 RSC member

£605 Non-member

£400 RSC student* member

£440 Student* non-member

* Student is undergraduate or post-graduate, not post-doc, and does not apply to students in paid employment.

Details of later fees may be found on our website.

Some student bursaries are available for this meeting (funded by the RSC-BMCS).

The closing date for applications is 16th April and the application form may be [downloaded here](#).

Venue and Accommodation

Hotel Comwell Borupgaard, Snekkersten is a 40-minute train or taxi journey from Copenhagen central railway station. Rooms are held at preferential rates at the conference venue, and the accommodation package includes dinners on Wednesday and Thursday nights.

Exhibition Opportunities

Exhibition stands are priced at £1,100, and this fee includes for one full delegate with access to the technical programme. Book early to avoid disappointment!

Delegate pack inserts may also be booked.

Sponsorship

We are grateful to our confirmed sponsors:

LEO Pharma

Lundbeck

AstraZeneca

Vipergen

Additional sponsors are sought.

Organising Committee

Sharan Bagal (chair)

Kevin Dack

Adrian Hall (treasurer)

Morten Jørgensen

Malin Lemurell

AstraZeneca, UK

LEO Pharma, Denmark

UCB, Belgium

Lundbeck, Denmark

AstraZeneca, Sweden

AstraZeneca



Vipergen

Secretariat Contact


Maggi Churchouse Events, UK, telephone +44 (0)1359 221004,
maggi@maggichurchouseevents.co.uk

Twitter Hashtag
#ANMC2019

Websites: www.maggichurchouseevents.co.uk/bmcs

Also: www.rsc.org/bmcs

Second announcement and call for posters



2nd RSC Anglo-Nordic Medicinal Chemistry Symposium

Tuesday-Friday, 11th-14th June 2019

Hotel Comwell Borupgaard, Snekkersten, Denmark



Who should attend

Medicinal chemists at all career stages. Scientists with an interest in drug discovery or new technologies that can be applied to the drug discovery process.

Programme Themes and Features

The scientific programme will feature themed lectures, focusing on medicinal chemistry and related technologies and disciplines across a range of drug targets and modalities. A distinguishing feature of this symposium is the collegiate style which encourages an atmosphere of information sharing and learning.

The event will include first rate lectures, poster session, trade exhibition, ample networking opportunities, welcome buffet on Tuesday, exceptional location, venue and accommodation.

Call for Posters

The call for papers is now open, and abstracts are invited for posters. The closing date is 30th April. Some posters will be selected for flash oral presentation.

Programme - draft

Tuesday 11th June

- 18.00 Welcome reception, registration, and buffet supper
- 21.00 Close

Wednesday 12th June

- 08.30 Registration
- Session 1 - Translational Regulation**
- 09.30 *Opening remarks*
Sharan Bagal, AstraZeneca and Chair of the Organising Committee, UK
- 09.40 *Keynote: Translating RNA sequence into lead small molecule medicines*
Matthew Disney, Scripps Research, USA
- 10.30 *Optimising PROTACs towards the clinic: turning promises of low dose and long duration into reality*
Ian Smith, GlaxoSmithKline, UK
- 11.10 Refreshments, exhibition and posters
- 11.40 *Discovery and characterization of highly potent and selective allosteric USP7 inhibitors*
Colin O'Dowd, Almac Discovery, UK
- 12.20 *Rewriting the (tran)script: discovery of Risdiplam*
Hasane Ratni, Roche, Switzerland
- 13.00 Lunch, exhibition and posters
- 14.00 Flash poster presentations
- 14.30 Dedicated poster session, refreshments
- Session 2 - Enabling Science and Technologies I**
- 16.00 *Late stage functionalisation of drug candidates using PolyCYPs® enzymes*
Lisbet Kvaerno, Hypha Discovery, UK
- 16.20 *Can a computer design a drug?*
John Cumming, pRED, F Hoffmann-La Roche, Switzerland
- 16.50 *Identification of nanomolar inhibitor of RuvBL1/2 from DNA-encoded small molecule library*
Iolanda Micco, Vipergen, Denmark
- 17.30 Close
- 19.00 Dinner (for residents only)

Programme - continued

Thursday, 13th June

- 08.30 Registration
- Session 3 - Enabling Science and Technologies II**
- 09.00 *Keynote: Prodrug strategies in medicinal chemistry*
Jarkko Rautio, University of Eastern Finland, Finland
- 09.50 *Structurally enabled discovery of innovative Calcitonin Gene-Related Peptide (CGRP) receptor antagonists*
Steve Watson, Heptares, UK
- 10.30 Refreshments, exhibition and posters
- 11.00 *Lowering lipophilicity by adding carbon - building bridges to improve physicochemical properties of drug molecules*
Sébastien Degorce, AstraZeneca, UK
- 11.30 *HIV nucleoside reverse transcriptase translocation inhibitors to enable extended duration dosing*
Izzat Raheem, MSD, USA
- 12.10 Lunch, exhibition and posters
- Session 4 - Drug Design Disclosures I**
- 14.00 *Discovery of GLPG2451, a novel potentiator for the treatment of cystic fibrosis*
Hans Kelgtermans, Galapagos, Belgium
- 14.40 *The Lundbeck approach to FBDD in the CNS drug space - from weak fragments to the PDE1 inhibitor development candidate*
Mauro Marigo, Lundbeck, Denmark
- 15.20 *Discovery of novel pyrido[2,3-b]pyrazine based small molecule pan-Fibroblast Growth Factor Receptor (FGFR) inhibitors and optimization into a potential clinical candidate*
Patrick Angibaud, Janssen, France
- 16.00 Refreshments, exhibition and posters
- 16.30 *AZD5718, a clinical inhibitor of Five-Lipoxygenase-Activating-Protein (FLAP) for treatment of Coronary Artery Disease (CAD)*
Daniel Pettersen, AstraZeneca, Sweden
- 17.10 *Identification of a novel oxadiazole ROR γ antagonist - a balancing act*
Morten Dahl Sørensen, LEO Pharma, Denmark
- 17.50 Close
- 19.00 Conference dinner (for residents only)

Friday, 14th June

- 08.30 Registration
- Session 5 - Drug Design Disclosures II**
- 09.00 *Target validation with chemical probes: reproducing pharmacology and safety aspects of the phenotype of Rorc-deficient mice with RORC2 inverse agonists in rats*
Samuel Hintermann, Novartis, Switzerland
- 09.40 *Discovery of the TYK2 selective inhibitor PF-6826647 for the treatment of Crohn's disease, and other autoimmune conditions*
Brian Gerstenberger, Pfizer Inc, USA
- 10.20 Refreshments, exhibition and posters
- 10.50 *Discovery of the oral LTC4S inhibitor AZD9898 as a new treatment for asthma*
Lena Ripa, AstraZeneca, Sweden
- 11.30 *Discovery of H3B-8800, a novel, orally bioavailable, small molecule, splice modulator*
Andrew Cook, H3 Biomedicine, USA
- 12.10 *Resetting the antibacterial arms race: LepB as a novel gram negative target*
James Crawford, Genentech, USA
- 12.50 Closing remarks, lunch and depart